Literature DB >> 27425618

Mesenchymal Tumors Can Derive from Ng2/Cspg4-Expressing Pericytes with β-Catenin Modulating the Neoplastic Phenotype.

Shingo Sato1, Yuning J Tang2, Qingxia Wei3, Makoto Hirata3, Angela Weng3, Ilkyu Han4, Atsushi Okawa5, Shu Takeda6, Heather Whetstone3, Puvindran Nadesan7, David G Kirsch8, Jay S Wunder9, Benjamin A Alman10.   

Abstract

The cell of origin for most mesenchymal tumors is unclear. One cell type that contributes to this lineages is the pericyte, a cell expressing Ng2/Cspg4. Using lineage tracing, we demonstrated that bone and soft tissue sarcomas driven by the deletion of the Trp53 tumor suppressor, or desmoid tumors driven by a mutation in Apc, can derive from cells expressing Ng2/Cspg4. Deletion of the Trp53 tumor suppressor gene in these cells resulted in the bone and soft tissue sarcomas that closely resemble human sarcomas, while stabilizing β-catenin in this same cell type caused desmoid tumors. Comparing expression between Ng2/Cspg4-expressing pericytes lacking Trp53 and sarcomas that arose from deletion of Trp53 showed inhibition of β-catenin signaling in the sarcomas. Activation of β-catenin inhibited the formation and growth of sarcomas. Thus, pericytes can be a cell of origin for mesenchymal tumors, and β-catenin dysregulation plays an important role in the neoplastic phenotype.
Copyright © 2016 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27425618      PMCID: PMC4963269          DOI: 10.1016/j.celrep.2016.06.058

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  73 in total

1.  KEGG: kyoto encyclopedia of genes and genomes.

Authors:  M Kanehisa; S Goto
Journal:  Nucleic Acids Res       Date:  2000-01-01       Impact factor: 16.971

2.  Generalized lacZ expression with the ROSA26 Cre reporter strain.

Authors:  P Soriano
Journal:  Nat Genet       Date:  1999-01       Impact factor: 38.330

3.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

4.  Aggressive fibromatosis (desmoid tumor) is derived from mesenchymal progenitor cells.

Authors:  Colleen Wu; Saeid Amini-Nik; Saied Nik-Amini; Puviindran Nadesan; William L Stanford; Benjamin A Alman
Journal:  Cancer Res       Date:  2010-09-14       Impact factor: 12.701

5.  The differentiation stage of p53-Rb-deficient bone marrow mesenchymal stem cells imposes the phenotype of in vivo sarcoma development.

Authors:  R Rubio; I Gutierrez-Aranda; A I Sáez-Castillo; A Labarga; M Rosu-Myles; S Gonzalez-Garcia; M L Toribio; P Menendez; R Rodriguez
Journal:  Oncogene       Date:  2012-12-10       Impact factor: 9.867

6.  Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss of Cdkn2.

Authors:  Alexander B Mohseny; Karoly Szuhai; Salvatore Romeo; Emilie P Buddingh; Inge Briaire-de Bruijn; Daniëlle de Jong; Melissa van Pel; Anne-Marie Cleton-Jansen; Pancras C W Hogendoorn
Journal:  J Pathol       Date:  2009-11       Impact factor: 7.996

Review 7.  Wnt pathway in osteosarcoma, from oncogenic to therapeutic.

Authors:  Yu Cai; Tiange Cai; Yan Chen
Journal:  J Cell Biochem       Date:  2014-04       Impact factor: 4.429

8.  A travel guide to Cytoscape plugins.

Authors:  Rintaro Saito; Michael E Smoot; Keiichiro Ono; Johannes Ruscheinski; Peng-Liang Wang; Samad Lotia; Alexander R Pico; Gary D Bader; Trey Ideker
Journal:  Nat Methods       Date:  2012-11-06       Impact factor: 28.547

9.  Pericytes of human skeletal muscle are myogenic precursors distinct from satellite cells.

Authors:  Arianna Dellavalle; Maurilio Sampaolesi; Rossana Tonlorenzi; Enrico Tagliafico; Benedetto Sacchetti; Laura Perani; Anna Innocenzi; Beatriz G Galvez; Graziella Messina; Roberta Morosetti; Sheng Li; Marzia Belicchi; Giuseppe Peretti; Jeffrey S Chamberlain; Woodring E Wright; Yvan Torrente; Stefano Ferrari; Paolo Bianco; Giulio Cossu
Journal:  Nat Cell Biol       Date:  2007-02-11       Impact factor: 28.824

Review 10.  Perivascular cells for regenerative medicine.

Authors:  Mihaela Crisan; Mirko Corselli; William C W Chen; Bruno Péault
Journal:  J Cell Mol Med       Date:  2012-12       Impact factor: 5.310

View more
  16 in total

Review 1.  Pericytes in the Premetastatic Niche.

Authors:  Ana E Paiva; Luiza Lousado; Daniel A P Guerra; Patrick O Azevedo; Isadora F G Sena; Julia P Andreotti; Gabryella S P Santos; Ricardo Gonçalves; Akiva Mintz; Alexander Birbrair
Journal:  Cancer Res       Date:  2018-05-22       Impact factor: 12.701

2.  Efficacy of auranofin as an inhibitor of desmoid progression.

Authors:  Kan Ito; Yoshihiro Nishida; Shunsuke Hamada; Koki Shimizu; Tomohisa Sakai; Bisei Ohkawara; Benjamin A Alman; Atsushi Enomoto; Kunihiro Ikuta; Hiroshi Koike; Jiarui Zhang; Kinji Ohno; Shiro Imagama
Journal:  Sci Rep       Date:  2022-07-13       Impact factor: 4.996

3.  Sarcoma Tumor Microenvironment.

Authors:  Panagiotis Tsagozis; Jordi Gonzalez-Molina; Anna-Maria Georgoudaki; Kaisa Lehti; Joseph Carlson; Andreas Lundqvist; Felix Haglund; Monika Ehnman
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

4.  Identification of CSPG4 as a promising target for translational combinatorial approaches in osteosarcoma.

Authors:  Federica Riccardo; Lidia Tarone; Selina Iussich; Davide Giacobino; Maddalena Arigoni; Federica Sammartano; Emanuela Morello; Marina Martano; Francesca Gattino; Raffaella De Maria; Soldano Ferrone; Paolo Buracco; Federica Cavallo
Journal:  Ther Adv Med Oncol       Date:  2019-06-06       Impact factor: 8.168

5.  Development of mouse models of angiosarcoma driven by p53.

Authors:  Donald M Salter; Meredyth Griffin; Morwenna Muir; Katy Teo; Jayne Culley; James R Smith; Laura Gomez-Cuadrado; Kylie Matchett; Andrew H Sims; Larry Hayward; Neil C Henderson; Valerie G Brunton
Journal:  Dis Model Mech       Date:  2019-07-09       Impact factor: 5.758

Review 6.  Chondroitin Sulfate Proteoglycan 4 and Its Potential As an Antibody Immunotherapy Target across Different Tumor Types.

Authors:  Kristina M Ilieva; Anthony Cheung; Silvia Mele; Giulia Chiaruttini; Silvia Crescioli; Merope Griffin; Mano Nakamura; James F Spicer; Sophia Tsoka; Katie E Lacy; Andrew N J Tutt; Sophia N Karagiannis
Journal:  Front Immunol       Date:  2018-01-10       Impact factor: 7.561

7.  Effects of chondroitin sulfate proteoglycan 4 (NG2/CSPG4) on soft-tissue sarcoma growth depend on tumor developmental stage.

Authors:  Shu-Hsuan Claire Hsu; Puviindran Nadesan; Vijitha Puviindran; William B Stallcup; David G Kirsch; Benjamin A Alman
Journal:  J Biol Chem       Date:  2017-12-01       Impact factor: 5.157

Review 8.  Glioblastoma-activated pericytes support tumor growth via immunosuppression.

Authors:  Isadora F G Sena; Ana E Paiva; Pedro H D M Prazeres; Patrick O Azevedo; Luiza Lousado; Sujit K Bhutia; Alla B Salmina; Akiva Mintz; Alexander Birbrair
Journal:  Cancer Med       Date:  2018-02-25       Impact factor: 4.452

Review 9.  Tissue Specific Origin, Development, and Pathological Perspectives of Pericytes.

Authors:  Tomoko Yamazaki; Yoh-Suke Mukouyama
Journal:  Front Cardiovasc Med       Date:  2018-06-27

10.  Tracing Tumor Evolution in Sarcoma Reveals Clonal Origin of Advanced Metastasis.

Authors:  Yuning J Tang; Jianguo Huang; Hidetoshi Tsushima; Ga I Ban; Hongyuan Zhang; Kristianne M Oristian; Vijitha Puviindran; Nerissa Williams; Xiruo Ding; Jianhong Ou; Sin-Ho Jung; Chang-Lung Lee; Yiqun Jiao; Benny J Chen; David G Kirsch; Benjamin A Alman
Journal:  Cell Rep       Date:  2019-09-10       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.